Dolutegravir and neural tube defects: a new insight

Lancet Infect Dis. 2020 Apr;20(4):405-406. doi: 10.1016/S1473-3099(20)30117-1.
No abstract available

Publication types

  • Letter

MeSH terms

  • Databases, Factual
  • Developed Countries
  • Developing Countries
  • Female
  • HIV Integrase Inhibitors / administration & dosage
  • HIV Integrase Inhibitors / adverse effects*
  • Heterocyclic Compounds, 3-Ring / administration & dosage
  • Heterocyclic Compounds, 3-Ring / adverse effects*
  • Humans
  • Neural Tube Defects* / chemically induced
  • Neural Tube Defects* / epidemiology
  • Oxazines
  • Pharmacovigilance*
  • Piperazines
  • Pyridones
  • Viral Load

Substances

  • HIV Integrase Inhibitors
  • Heterocyclic Compounds, 3-Ring
  • Oxazines
  • Piperazines
  • Pyridones
  • dolutegravir